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REVIEW
Abstract: The antithrombin binding sequence of heparin, a pentasaccharide, has been
synthesized as fondaparinux, an indirect, selective, and reversible factor Xa inhibitor. It can
be administered subcutaneously, is well absorbed, and has a half-life of c. 17 hours permitting
once-daily injection. It has been evaluated in an extensive study program in major orthopedic
surgery, including hip fracture, and in major abdominal surgery with a large proportion of
surgery for cancer. The effect is at least as effective as for low-molecular-weight heparins and
it has also been shown effective for extended prophylaxis in hip fracture patients. Several
thousands of patients have been studied and the substance is safe, although a slightly higher
frequency of bleedings is found than in patients on low-molecular-weight heparins. There is
no specific antidote but if necessary, recombinant activated factor VII can be used. Other
side-effects are rare. Fondaparinux is cost saving and sometimes cost neutral when compared
with enoxaparin.
Keywords: fondaparinux, venous thrombosis, venous thromboembolism, surgery, orthopedic
surgery, major abdominal surgery, bleeding complications
Introduction
Low-molecular-weight heparins are effective and safe to motivate their use for
prevention of post-operative venous thromboembolism (VTE), and they are probably
the dominating pharmacological principle in this respect (Geerts et al 2002). In the
very beginning of the low-molecular-weight heparin era it was considered important
to have a high factor Xa inhibitor activity which ideally should be higher than the IIa
inhibitor activity, but over the years the discussion came to focus on the optimal
balance between inhibiting factor Xa and factor IIa. It was therefore of great theoretical
interest when selective Xa inhibitors were identified, because it was then possible to
answer the question: is it possible to obtain a good prophylactic effect by focusing
on just one of the factors in the coagulation system? The discussion alluded to above
on the role of Xa inhibition in the infancy of low-molecular-weight heparins could
thereby be further argumued. The aim of this paper is to summarize present-day
knowledge on the prophylactic effect of fondaparinux, a purely synthetic selective
indirect inhibitor of factor Xa, the first representative of a new class of antithrombotic
substances (Cheng 2002; Hoppensteadt et al 2003; Nijkeuter and Huisman 2004).
Inhibition of factor Xa (Figure 1)
The mixture of polysulfated glycosaminoglycans called heparin binds to and activates
antithrombin. The heparin–antithrombin complex inhibits the serine proteases in the
coagulation system, including factor Xa. By fragmenting the heparin molecule to
low-molecular-weight heparins, a relatively greater inhibitory effect on factor Xa is
obtained. The minimum molecular sequence of heparin, which is necessary to bind
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antithrombin, was shown to be a pentasaccharide described
by Lindahl et al (1979) and synthesized by Choay et al
(1983) as the pharmacological substance fondaparinux
(molecular weight 1728 Da). It is an indirect, selective factor
Xa inhibitor without interaction with factor II or platelets.
TFPI (tissue factor pathway inhibitor) is not released by
fondaparinux in contrast to heparins. The binding between
fondaparinux and antithrombin is non-covalent and
reversible. Also, when antithrombin in plasma has been
saturated, circulating free fondaparinux has no anticoagulant
effect by itself and is renally excreted. When the
conformationally altered antithrombin binds to factor Xa,
fondaparinux is released and can continue the process, acting
as a catalyst. Fondaparinux is approved in Europe and by
the FDA (Food and Drug Administration) at a dosage of
2.5 mg/day s.c. to be used for prevention of venous
thromboembolism in major orthopedic surgery (specified
as total hip and knee arthroplasty and hip fracture surgery).
The bioavailability is 100% and maximal plasma
concentration is seen at 2 hours with an elimination half-
life of around 17 hours, which permits once-daily dosage
(Bauer et al 2002). The excretion is in unmetabolized form
through the kidneys, which motivates caution and dose
modification in patients with impaired kidney function. In
patients with a creatinine clearance of less than 30 mL/min
fondaparinux is contraindicated. Because of the relatively
long half life and its prolongation in patients with renal
insufficiency, there has been a concern regarding
reversibility. This is a potential problem should severe
bleeding occur or emergent surgery be indicated. From a
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Figure 1 Schematic drawing of the coagulation cascade and the sites of action of the antithrombotic agents fondaparinux (Xa inhibition), heparin, and low-molecular-
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practical point of view but based on experiments in healthy
volunteers, and with the duration between 2 and 6 hours,
recombinant factor VIIa may be used intravenously
(Bijsterveld et al 2002). Case reports are coming on the
clinical value of recombinant factor VIIa to reverse bleeding
complications after fondaprinux (Huvers et al 2005).
Clinical study program
After having established the mechanism of action it is
important to choose a reasonably correct dose and
administration routine to be used with the most relevant
patient populations. For some time it has been considered
appropriate to start with major orthopedic surgery with rather
standardized surgical procedures and high risk to develop
venous thromboembolism. This study model was used for
fondaparinux, where the initial program evaluated several
thousand patients undergoing elective hip and knee
arthroplasty or hip fracture surgery, the comparator being
enoxaparin. This documentation has lead to approval in
several countries as prophylaxis for these indications. Later
on, studies on high-risk abdominal surgery have been
performed. Before starting the large-scale clinical evaluation
program a dose finding study was performed in 993 patients
undergoing total hip replacement, where the optimal dose
from a risk–benefit point of view was defined as 2.5 mg
once daily with start 6±2 hours post-operatively (Turpie et
al 2001). The phase III program of today has included more
than 15 000 patients.
Prophylactic effect of fondaparinux
(Table 1)
Studies on post-operative prophylaxis have included more
than 10 000 patients. The four key phase III studies on 7344
orthopedic patients (Bauer et al 2001; Eriksson et al 2001;
Lassen et al 2002; Turpie et al 2002) (trial acronyms
EPHESUS (elective hip), PENTAMAKS (elective knee),
PENTHIFRA (hip fracture), PENTAHLON (elective hip))
have been summarized in a meta-analysis (Turpie et al 2002).
The ability to reduce venographically detected deep vein
thrombosis and symptomatic venous thromboembolism is
clear and significantly better than the comparator which has
been the low-molecular-weight heparin enoxaparin, in two
studies with the European regimen (40 mg daily with pre-
operative start) and in two with the American (30 mg twice
daily with post-operative start). The overall result was a
55% common odds reduction in favor of fondaparinux (95%
CI 46%–63%) in risk of VTE (13.7 vs 6.8%; p<0.001). The
effect is true also when proximal deep vein thrombosis is
considered (2.9 vs 1.3%) but less clear or non-existent when
the focus of analysis is put on clinically established venous
thromboembolism or mortality (no difference), a fact which
has been used as an argument against fondaparinux (see for
instance (Vormfelde 2002; Lowe et al 2003)). Fatal
pulmonary embolism was seen in two fondaparinux and
three enoxaparin patients. Subgroup analyses showed that
the beneficial effect of fondaparinux was found regardless
of gender, age, body mass index, duration of surgery, use of
cement, and type of anesthesia (Turpie et al 2002). After
the publication of the fondaparinux studies the ACCP
(American College of Chest Physicians) conference on
antithrombotic therapy (Geerts et al 2004) and the European
Committee for Proprietary Medicinal Products (CPMP
2000) have proposed not taking asymptomatic distal deep
vein thrombosis into consideration. This view has also been
taken in a letter to the Lancet by Lowe et al (2003). The
fondaparinux results were therefore re-analyzed (Turpie et
al 2004) and using the ACCP definition the results were
1.7% and 3.3% respectively (reduction of 49.6%, p<0.001)
and with CPMP 2.1 and 3.9% respectively (reduction of
48% p<0.01).
After these four key studies the evaluation program
continued to study the indication prolonged prophylaxis in
hip fracture surgery (Eriksson and Lassen 2003), an
approach that was further motivated by the finding in a
logistic regression analysis of the four first studies that a
longer duration of fondaparinux was associated with a lower
incidence of venous thromboembolism (Andersen 2004).
Extending the prophylaxis from around 7 days to around
30 days reduced venographic deep vein thrombosis from
35% to 1.4% (p<0.001). This is obviously an exceptionally
Table 1 Studies on the prophylactic effect of fondaparinux on
post-operative venous thromboembolism
Study and type of patients No of  Summary effect
patients (ARR and RRR)
EPHESUS, hip replacement
a 1827 5.1% 56%
PENTATHLON, hip replacementa 1584 2.2% 26%
PENTHIFRA, hip fracture
a 1250 10.8% 56%
PENTAMAKS, knee replacement
a 0 724 15.3% 55%
PEGASUS, major abdominalb 2927 1.5% 25%
APOLLO, major abdominal
c 1070 3.6% 68%
PENTHIFRA plus, hip fracture
d, 0 656 33.6% 96%
prolonged prophylaxis
aComparator enoxaparin.
bComparator dalteparin.
cFondaparinux or placebo in addition to intermittent pneumatic compression.
dFondaparinux once daily for one week followed by placebo or fondaparinux for
around four weeks.
Abbreviations: ARR, absolute risk reduction; RRR, relative risk reduction.Vascular Health and Risk Management 2006:2(4) 368
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good prophylactic result. A similar reduction was found for
proximal deep vein thrombosis (15.8%–0.9%) and
symptomatic venous thromboembolism (2.7%–0.3%,
p<0.02).
In the orthopedic studies fondaparinux has been
instituted post-operatively. In a post-hoc analysis it was
shown that delaying the start to between 6 and 9 hours post-
operatively reduced the risk of bleeding complications
significantly, without diminishing the effectivity (Turpie et
al 2002). In an open randomized study on 2000 elective hip
patients with blinded adjudication of clinically documented
venous thromboembolism, it was further shown that
delaying the first dose of fondaparinux from 6 to 8 hours
post-operatively to the first post-operative morning did not
influence the outcome (1.9% VTE vs 1.8%) (Davidsson et
al 2005). Thus fondaparinux can be started post-operatively
and therefore does not increase surgical bleeding.
Another high risk group of importance to study is found
within the various indications for abdominal surgery. In a
recently published trial (PEGASUS) in 2927 high risk
abdominal surgery 2.5 mg fondaparinux started 6 hours after
surgery was compared with dalteparin started 2 hours before
the operation (the first two doses of 2500 units and thereafter
5000 units daily) (Agnelli et al 2005). The study was
designed as a non-inferiority trial and the hypothesis was
verified. The frequency of venographically detected deep
vein thrombosis on day 10 in the efficacy analysis of 2048
patients was 4.6% in the fondaparinux group and 6.1 % in
the dalteparin group, a relative risk reduction of 25% (95%
CI – 9.0%–47.9%). In the subgroup of 1408 patients
(69%) operated on for cancer, the corresponding
frequencies of thrombosis were 4.7% and 7.7%
respectively (p<0.01). The frequency of symptomatic-
adjudicated venous thromboembolic events was 0.4% in
both groups.
In the APOLLO study with 1070 patients (Turpie et al
2005) once daily fondaparinux combined with intermittent
pneumatic compression was significantly more effective
than intermittent pneumatic compression alone to prevent
venous thromboembolism after major abdominal surgery.
Of 842 patients included in the efficacy analysis (cancer
surgery 39%), the frequency of venous thromboembolism
was reduced from 5.3% to 1.7% (p<0.004).
In a recently published multicenter placebo-controlled
trial it was shown that fondaparinux also has a significant
effect in preventing VTE in acutely ill medical patients
(Cohen et al 2006).
Safety, side-effects
The main concern is whether fondaparinux may induce
bleeding complications as, by its mechanism of action, it
influences the hemostatic system. Generally, fondaparinux
has been well tolerated. Fondaparinux does not influence
platelet function. In the early dose finding study the
incidence of major bleeding was significantly dose-related
(Turpie et al 2001). In the studies on hip surgery (both
arthroplasty and hip fracture) the frequency of major
hemorrhagic events did not differ between the fondaparinux
and enoxaparin groups. In the study on major knee surgery
(Bauer et al 2001) the frequency of major bleeding
complications was 2.1% in the fondaparinux group vs 0.2%
in the enoxaparin group, a difference which was highly
significant (p<0.006). In a meta-analysis (Turpie et al 2002)
of all four short-time orthopedic studies the frequency of
adjudicated major bleeding events in the fondaparinux group
was significantly higher than in the enoxaparin group (2.9%
vs 1.7%; p<0.008). The difference was mainly driven by a
difference in the so called bleeding index (≥2). There was
no difference in fatal bleeding, or bleeding leading to re-
operation or in a critical organ (Nijkeuter and Huisman
2004). One important finding in a post hoc analysis was the
significant frequency of major bleeding whether the first
fondaparinux injection was given <6 hours after wound
closure or ≥6 hours after (3.2% vs 2.1% p=0.045 (Turpie et
al 2002).
In the study in patients undergoing abdominal surgery
(Agnelli et al 2005) the frequency of major bleedings was
3.4% vs 2.4% in the dalteparin group (p<0.122). There were
two fatal bleedings in each group (0.1%). The effect of
timing of the first fondaparinux injection was similar to the
orthopedic studies with 6 hours post-operatively as the
divider (3.4% vs 2.8%, NS). In the APOLLO study major
bleeding was significantly more frequent in the fondaparinux
group compared with the placebo group, 1.6% vs 0.2%
(p<0.006) (Turpie et al 2005).
Thrombocytopenia is seen at a similar frequency after
enoxaparin and dalteparin and there are no reports of serious
HIT (heparin induced thrombocytopenia). In the study on
extended prophylaxis after hip fracture there was no increase
in liver enzymes (Lassen et al 2003). Because of the long
half-life there is a concern about the risk of spinal
hematoma in patients with epidural anesthesia but hitherto
no cases have been reported with the 2.5 mg dose. Special
concern should be given to patients with impaired renal
function.Vascular Health and Risk Management 2006:2(4) 369
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Up till now there are no reports on drug interactions
(Reynolds et al 2004). Specific studies have been made with
warfarin, aspirin, and piroxicam, no interaction being found
(Keam and Goa 2002).
There have been no differences reported in mortality
between the fondaparinux and comparators in the various
studies. As indicated above, one important concern when
discussing fondaparinux is the current lack of an antidote.
Aspects on health economy
In addition to studies showing new substances to be effective
and safe, in a reality with restrained resources it is also
important to put a health economic perspective to the new
methodology. One problem performing such studies is the
differences between countries; another is to draw
conclusions from well defined trial data to everyday health
care. To overcome at least some of the difficulties, models
are used where various assumptions are made and included
in sensitivity analyses to establish the robustness of the
outcome data. There are now several pharmacoeconomic
studies showing that fondaparinux compares favorably with
enoxaparin in major orthopedic surgery (Lobo 2003;
Reynolds et al 2004). In some studies, especially Spanish
and UK trials, enoxaparin was cost saving at discharge, but
in the long run fondaparinux became cost neutral or even
cost saving. Health economic studies on long-term
consequences such as post-thrombotic syndrome have not
been undertaken.
Conclusion
Fondaparinux, a new selective indirect inhibitor of activated
factor X, has been shown to be as effective as or even better
than low-molecular-weight heparins to prevent post-
operative venous thromboembolic complications, both after
major orthopedic and major abdominal surgery. The
bleeding risk is small.
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